Zentalis Pharmaceuticals, Inc.
ZNTL
$1.43
-$0.08-5.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -94.97M | -40.16M | -88.28M | 10.07M | -60.92M |
| Total Depreciation and Amortization | 317.00K | 321.00K | 327.00K | 324.00K | 337.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.09M | 3.05M | 38.71M | -46.06M | 9.71M |
| Change in Net Operating Assets | -7.08M | -7.26M | 14.10M | -16.31M | 10.27M |
| Cash from Operations | -39.70M | -44.05M | -35.14M | -51.97M | -40.60M |
| Capital Expenditure | 0.00 | 0.00 | -181.00K | -40.00K | -173.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 65.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.28M | 48.24M | 34.61M | 61.59M | -41.89M |
| Cash from Investing | 32.28M | 48.24M | 34.49M | 61.55M | -42.06M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 92.00K | 9.00K | 248.00K | 0.00 |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -241.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 92.00K | 9.00K | 7.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.42M | 4.29M | -640.00K | 9.58M | -82.66M |